Press Releases

  • Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

  • Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

  • VolitionRx Limited Corrects an Earlier Announcement

  • VolitionRx Limited to Present at Multiple Investor Conferences in June

  • A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

  • VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

  • VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update

  • Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

  • Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory

  • VolitionRx Appoints David Vanston as Chief Financial Officer

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus